Dermatology & Plastic Surgery Institute Outcomes
Surgical Quality Improvement
Brain Tumor Surgery Outcomes
Brain Tumor Surgery ACS NSQIP Outcomes
January 1, 2024– December 31, 2024
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall brain tumor surgery ACS NSQIP performance benchmarked against 222 participating sites.
Brain Tumor (222 Sites) | N | Observed | Expected |
---|---|---|---|
30 Day Mortality | 316 | 1.90% | 1.69% |
30 Day Morbidity | 316 | 12.03% | 8.45% |
Unplanned Intubation | 316 | 3.48% | 1.59% |
Ventilator > 48 Hours | 314 | 3.82% | 1.21% |
Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 316 | 3.16% | 2.73% |
Renal Failure | 316 | 0.95% | 0.31% |
Urinary Tract Infection (UTI) | 315 | 2.22% | 1.19% |
Surgical Site Infection (SSI) | 316 | 2.22% | 1.88% |
Sepsis | 316 | 1.27% | 1.09% |
C.diff Colitisᵃ | 316 | 1.58% | 0.17% |
Unplanned Reoperation | 316 | 3.80% | 4.20% |
Length of Stayᵇ | 270 | 10.00% | 22.55% |
Unplanned Readmission | 316 | 9.49% | 9.18% |
American College of Surgeons National Surgical Quality Improvement Program, 2025.
ACS NSQIP® Semiannual Report July, 2025, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.
ᵇIdentified as a statistical outlier (lower than expected) by the ACS NSQIP hierarchical model.